Dalargin-Ellara® (Dalargin-Ellara)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceTyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine diacetateTyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine diacetate
Similar drugsTo uncover
  • Dalargin
    lyophilizate w / m in / in 
    FGBU RKNPK ROSZDRAVA - EPMPP     Russia
  • Dalargin-Deco
    lyophilizate w / m in / in 
    Company DEKO, LLC     Russia
  • Dalargin-Ellara®
    lyophilizate w / m in / in 
    ELLARA, LTD.     Russia
    • Dosage form: & nbsplyophilizate for the preparation of solution for intravenous and intramuscular administration
    Composition:
    In 1 ampoule contains: dalargin (tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine diacetate) - 1 mg.
    Description:
    White amorphous powder or porous mass. The smell of acetic acid is allowed.
    Pharmacotherapeutic group:Peptic ulcer treatment - regulatory peptide
    ATX: & nbsp

    A.02.B.X   Other antiulcer drugs

    Pharmacodynamics:
    A substance of peptide nature, a synthetic hexapeptide, an endogenous antagonist of opioid receptors. Suppresses proteolysis and promotes the healing of stomach and duodenal ulcers. Has a moderate antisecretory activity, reduces the acidity of gastric juice. Suppresses the external secretion of the pancreas in response to various stimuli (food, secretin, etc.). When the pancreas is damaged in the experiment, it is shown that the drug reduces hyperfermentation,limits the foci of necrosis and promotes their replacement with a full-length tissue, weakens the synthesis of proteolytic enzymes by the pancreas. Has a slight hypotensive effect.
    Pharmacokinetics:Pharmacokinetics studies were not performed
    Indications:
    As a part of the combined therapy for peptic ulcer of the stomach and duodenal ulcer in the acute phase, acute pancreatitis, pancreatic necrosis.
    Contraindications:
    Hypersensitivity, arterial hypotension, acute infectious processes, pregnancy, the period of breastfeeding, children's age.
    Dosing and Administration:
    Intravenous or intramuscular. Immediately before use, the contents of the ampoule are dissolved in 1 ml of 0.9% sodium chloride solution for injection. With exacerbations of peptic ulcer of the stomach and duodenum, the drug is administered intravenously or intramuscularly at a dose of 1 mg. The highest daily dose of 5 mg. The course of treatment is 3-4 weeks. The total dose for the course of treatment is 30-50 mg.
    In acute pancreatitis, the drug is administered intravenously at a dose of 2 mg, then 5 mg 1-2 times a day. The course of treatment is 4-6 days.
    With pancreonecrosis, intravenously administered 5 mg 3-4 times a day (after 6-8 hours).The course of treatment is from 2 to 6 days.
    Side effects:
    Allergic reactions, lowering blood pressure.
    Overdose:
    At present, no cases of drug overdose have been reported.
    Interaction:
    No data available.
    Special instructions:
    The use of the drug during pregnancy, during breastfeeding, children is contraindicated. Information about the features of the use of adults with chronic diseases, there are no.
    Effect on the ability to drive transp. cf. and fur:
    During the treatment period, due to possible side effects (lowering blood pressure, which can lead to dizziness and visual impairment), it is advisable to use caution when dealing with potentially dangerous activities requiring increased concentration of attention and speed of psychomotor reactions, driving.
    Form release / dosage:
    Lyophilizate for the preparation of solution for intravenous and intramuscular injection, 1 mg.
    Packaging:
    1 mg per ampoule of neutral glass.
    5 ampoules per contour cell packaging made of polyvinyl chloride film.1 or 2 contoured cell packs of PVC together with instruction for use and scarifier ampoule in a pack of cardboard. 5 or 10 ampoules together with the instruction for use and scarifier ampoule in a pack of cardboard with a corrugated liner.
    When using ampoules with a dot or a ring of fracture, the ampoule scaper does not insert
    Storage conditions:
    In the dark place at a temperature of no higher than 20 ° C. Keep out of the reach of children.
    Shelf life:
    3 years. Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:LS-001304
    Date of registration:12.10.2011 / 02.09.2013
    Expiration Date:Unlimited
    The owner of the registration certificate:ELLARA, LTD. ELLARA, LTD. Russia
    Manufacturer: & nbsp
    Information update date: & nbsp18.03.2017
    Illustrated instructions
      Instructions
      Up
      talkdrugs

      +8 (800)555-35-35

      [email protected]

      The reference book of medicines of the Publishing Group "GEOTAR-Media" - the leader in the field of professional medical and pharmaceutical literature.

      The information on the preparations placed on the site is intended only for specialists.Drug descriptions can not be used by patients to make an independent decision on their use.

      It is forbidden to copy any instructions of medicinal products, biologically active additives or other information from the site www.talkdrugs.info without the written permission of the Publishing House "GEOTAR".

      All rights reserved. © Publishing group "GEOTAR-Media" 2008-2016.